Data from Hansa Medical’s First Phase II study of IdeS in Sensitized Kidney Transplantation Patients Presented in Oral Session at ESOT 2015
“The data clearly support further development in transplantation and we are pleased that the investigators were given the opportunity to present these interesting and encouraging data at this renowned congress” states Dr. Christian Kjellman, Chief Scientific Officer of Hansa Medical AB.
In an oral presentation today, Tomas Lorant MD, PhD, at Uppsala University Hospital and principal investigator of the clinical study reported that the MFI of HLA antibodies were significantly reduced in all patients treated with IdeS. Even though it was not an objective of the study one patient with donor specific antibodies who was on the waiting list was offered a kidney and was subsequently successfully transplanted after having received 2 doses of IdeS at a 30-hour interval. Positive cytotoxic and flow cytometry crossmatch tests against the donor were converted to negative as a result of the IdeS treatment. The transplanted kidney is well functioning with no signs of antibody-mediated rejection. Four infections and one case of myalgia possibly related to IdeS were reported in the study. Dr. Lorant concludes that treatment with IdeS significantly reduces HLA antibody levels and that IdeS has an acceptable safety profile. An abstract with the title “Rapid removal of anti-HLA antibodies in immunized patients awaiting renal transplantation – A dose finding study of the IgG degrading enzyme IdeS” from the presentation is available at the ESOT congress website under Abstract Program: http://esot2015.esot.org/abstracts
The information in this press release is disclosed pursuant to the Securities Markets Act or the Financial Instruments Trading Act. The information was released for public disclosure on September 15, 2015 at 08.30 CET.
För ytterligare information, vänligen kontakta:
Hansa Medical AB
Göran Arvidson, VD
Mobiltelefon: 46 70-390 85 30